Cited by 723HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Open access

Venter, Willem D.F., Moorhouse, Michelle, Sokhela, Simiso, Fairlie, Lee, Mashabane, Nkuli, Masenya, Masebole, Serenata, Celicia, Akpomiemie, Godspower, Qavi, Ambar, Chandiwana, Nomathemba, Norris, Shane, Chersich, Matthew, Clayden, Polly, Abrams, Elaine, Arulappan, Natasha, Vos, Alinda, McCann, Kaitlyn, Simmons, Bryony, Hill, Andrew·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1902824

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries. METHODS: We conducted a 96-week, phase 3, investigator-led, open-label, randomized trial in South Africa, in which we compared a triple-therapy combination of emtricitabine (FTC) and DTG plus either of two tenofovir prodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against the local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group). Inclusion criteria included an age of 12 years or older, no receipt of ART in the previous 6 months, a creatinine clearance of more than 60 ml per minute (>80 ml per minute in patients younger than 19 years of age), and an HIV type 1 (HIV-1) RNA level of 500 copies or more per milliliter. The primary end point was the percentage of patients with a 48-week HIV-1 RNA level of less than 50 copies per milliliter (as determined with the Snapshot algorithm from the Food and Drug Administration; noninferiority margin, -10 percentage points). We report the primary (48-week) efficacy and safety data. RESULTS: A total of 1053 patients underwent randomization from February 2017 through May 2018. More than 99% of the patients were black, and 59% were female. The mean age was 32 years, and the mean CD4 count was 337 cells per cubic millimeter. At week 48, the percentage of patients with an HIV-1 RNA level of less than 50 copies per milliliter was 84% in the TAF-based group, 85% in the TDF-based group, and 79% in the standard-care group, findings that indicate that the DTG-containing regimens were noninferior to the standard-care regimen. The number of patients who discontinued the trial regimen was higher in the standard-care group than in the other two groups. In the per-protocol population, the standard-care regimen had equivalent potency to the other two regimens. The TAF-based regimen had less effect on bone density and renal function than the other regimens. Weight increase (both lean and fat mass) was greatest in the TAF-based group and among female patients (mean increase, 6.4 kg in the TAF-based group, 3.2 kg in the TDF-based group, and 1.7 kg in the standard-care group). No resistance to integrase inhibitors was identified in patients receiving the DTG-containing regimens. CONCLUSIONS: Treatment with DTG combined with either of two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the standard-care regimen. There was significantly more weight gain with the DTG-containing regimens, especially in combination with TAF, than with the standard-care regimen. (ADVANCE ClinicalTrials.gov number, NCT03122262.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1902824

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe
Mika Kivimaki, B., Kuosma, E., Ferrie, J. E., Luukkonen, R. A., Nyberg, S. T., Alfredsson, L. S., Batty, G. D., Brunner, E. J., Fransson, E. I., Goldberg, M., et al. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30074-9 · Cited by 695
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Sax, P. E., Pozniak, A., Montes, M., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 394
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
Zash, R., Makhema, J. M., & Shapiro, R. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1807653 · Cited by 379
Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens
Norwood, J., Turner, M. M., Bofill, C., Rebeiro, P. F., Shepherd, B. E., Bebawy, S. S., Hulgan, T., Raffanti, S. P., Haas, D. W., Sterling, T. R., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001525 · Cited by 285
Brief Report
Walmsley, S. L., Baumgarten, A., Berenguer, J., Felizarta, F., Florence, É., Khuong-Josses, M.-A., Kilby, J. M., Lutz, T., Podzamczer, D., Portilla, J., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000790 · Cited by 225
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Kanters, S., Vitória, M., Doherty, M. C., Socias, M. E., Ford, N. P., Forrest, J. I., Popoff, E., Bansback, N. J., Nsanzimana, S., Thorlund, K., et al. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30091-1 · Cited by 210
Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors
Bakal, D. R., Coelho, L. E., Luz, P. M., Clark, J. L., Boni, R. B. D., Cardoso, S. W., Veloso, V. G., Lake, J. E., & Grinsztejn, B. G. J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky145 · Cited by 188
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Wohl, D. A., Yazdanpanah, Y., Baumgarten, A., Clarke, A. E., Thompson, M., Brinson, C. C., Hagins, D. P., Ramgopal, M. N., Antinori, A., Wei, X., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30077-3 · Cited by 168

Show all 31 references

Research works printed but not linked: 2

Doherty M. New directions in the 2015 WHO Consolidated ARV Guidelines: testing new directions in treatment and measuring impact. Presented at the Eighth International AIDS Society Conference Vancouver BC Canada July 19–22 2015.
Beyrer C, Pozniak A. HIV drug resistance. N Engl J Med 2018;378:875-875.29490186

Sorted by citations

Items 401–500 of 719

High rates of viral suppression in pregnancy drop postpartum in South African women on tenofovir‐lamivudine‐dolutegravir: a prospective cohort study
Abrams, E. J., Jao, J. K., Mukonda, E. E., Madlala, H. P., Matyseni, S., Zerbe, A., Legbedze, J., & Myer, L. (2025) · Journal of the International AIDS Society · doi:10.1002/jia2.70044 · Cited by 5
Self-citation
Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV
Cindi, Z., Kawuma, A. N., Maartens, G., Bradford, Y., Sokhela, S. M., Chandiwana, N. C., Venter, F., Wasmann, R. E., Denti, P., Wiesner, L., et al. (2023) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000495 · Cited by 5
Self-citation
Antiretroviral therapy among people with HIV with comorbidities in the United States: a retrospective cohort study
Buysman, E. K., Kumar, P. N., McNiff, K., Goswami, S., Paudel, M. L., Prajapati, G., & Tadese, B. K. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2262379 · Cited by 5
Effect of dolutegravir-based drug combinations on the level of medication adherence and viral load among adolescents living with HIV in resource-limited setting: a pre-post design
Ezenwosu, I. L., Onu, J. U., Chukwuma, U. V., Chima, O. K., Omotola, O. F., Ezenwosu, O. U., & Chukwuka, C. (2023) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh-2023-0082 · Cited by 5
Association of Integrase Strand Transfer Inhibitor-Based Antiretroviral Therapy With Blood Pressure and Sustained Hypertension in People With Human Immunodeficiency Virus
Siddiqui, M., Burkholder, G., Judd, E. K., Wang, Z., Colantonio, L. D., Ghazi, L., Shimbo, D., Willig, A. L., Overton, E. T., Oparil, S., et al. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae078 · Cited by 5
Integrated PrEP and STI Services for Transgender Women in Uganda: Qualitative Findings from a Randomized Trial
Mujugira, A., Nakyanzi, A., Bagaya, M., Mugisha, J., Kamusiime, B., Nalumansi, A., Kasiita, V., Ssebuliba, T., Nampewo, O., Nsubuga, R., et al. (2024) · AIDS and Behavior · doi:10.1007/s10461-024-04469-x · Cited by 5
Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study
Zhang, Q., Xu, J., Liu, D., Wang, L., Ren, S., Zheng, S., Chen, X., Li, Q., & Lu, J. (2024) · Antiviral Therapy · doi:10.1177/13596535241284226 · Cited by 5
High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana
Choga, O. T., Lemogang, G. M., Choga, W. T., Muzanywa, G., Shadreck, T. M., Ralegoreng, C., Maruapula, D., Moraka, N. O., Koofhethile, C. K., Mokgethi, P. T., et al. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae472 · Cited by 5
Prevalence and associated factors of metabolic syndrome among people living with HIV in a medical center of Northern Taiwan
Tu, C.-A., Kuo, C.-F., Lee, C.-M., Liu, C.-P., Tseng, H.-K., Huang, T.-Y., Lin, C., Chang, H. L., Lee, W. Y.-N., Sun, F., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-88552-w · Cited by 5
Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India
Dravid, A. N., Betha, T., Ak, S., Gawali, R., Mahajan, U. S., Kulkarni, M. M., Saraf, C. K., Kore, S., Dravid, M., & Rathod, N. (2020) · HIV Medicine · doi:10.1111/hiv.12912 · Cited by 5
The Association Between Weight Gain, Sex, and Immune Activation Following the Initiation of Antiretroviral Therapy
Bares, S. H., Smeaton, L. M., Scott, S., Smith, B. A., Godfrey, C. C., & McComsey, G. A. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab210 · Cited by 5
Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study)
Gómez‐Ayerbe, C., Palacios, R., Mayorga, M., Navarrete, M. N., Murcia, S. F., Ruiz, I., Garcia, C., Castaño, M., Merino, D., Collado, A., et al. (2022) · International Journal of STD & AIDS · doi:10.1177/09564624221125356 · Cited by 5
Preventing and diagnosing HIV-related comorbidities in adolescents.
Yusuf, H. E., Griffith, D., & Agwu, A. L. (2022) · PubMed Central · Cited by 5
Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV
Guaraldi, G., Milić, J., Bacchi, E., Carli, F., Menozzi, M., Franconi, I., Raimondi, A., Ciusa, G., Masi, V., Belli, M., et al. (2023) · HIV Research & Clinical Practice · doi:10.1080/25787489.2022.2150815 · Cited by 5
Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial)
Bousmah, M., Protopopescu, C., Mpoudi-Etame, M., Bassega, P. O., Maradan, G., Olinga, J., Varloteaux, M., Sanchez, T. T., Delaporte, É., Kouanfack, C., et al. (2023) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003273 · Cited by 5
Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe
Kouamou, V., Washaya, T., Mapangisana, T., Ndhlovu, C. E., & Manasa, J. (2024) · AIDS · doi:10.1097/qad.0000000000003830 · Cited by 5
Effect of metabolic status on response to SIV infection and antiretroviral therapy in nonhuman primates
Webb, G. M., Sauter, K. A. D., Takahashi, D. L., Kirigiti, M. A., Bader, L., Lindsley, S. R., Blomenkamp, H., Zaro, C., Shallman, M., McGuire, C. M., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.181968 · Cited by 5
Significant Publications on Infectious Diseases Pharmacotherapy in 2019
Hendrickson, J. A., Spitznogle, S. L., Gonzales-Luna, A. J., Babic, J. T., Britt, R. S., Knight, J. M., Pham, S. N., & McDaneld, P. M. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020951348 · Cited by 5
Emerging drugs for the treatment of HIV/AIDS: a review of 2019/2020 phase II and III trials
Piscaglia, M., Cossu, M. V., Passerini, M., Petri, F., Gerbi, M., Fusetti, C., Capetti, A. F., & Rizzardini, G. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1946036 · Cited by 5
Short-term Neuropsychiatric and Body Weight Changes in Patients Switching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69)
Tiraboschi, J. M., Prieto, P., Saumoy, M., Silva, A., Imaz, A., Scévola, S. C., Fernandez, G., Navarro, A., Piatti, C. S., & Podzamczer, D. (2022) · Current HIV Research · doi:10.2174/1570162x20666220608160335 · Cited by 5
RETRACTED: Synthesis and Evaluation of Anti-HIV Activity of Mono- and Di-Substituted Phosphonamidate Conjugates of Tenofovir
Qureshi, A., Ouattara, L. A., El‐Sayed, N. S., Verma, A., Doncel, G. F., Choudhary, M. I., Siddiqui, H. L., & Parang, K. (2022) · Molecules · doi:10.3390/molecules27144447 · Cited by 5
Retracted
The effect of a treatment switch to integrase Strand transfer inhibitor–based regimens on weight gain and other metabolic syndrome-related conditions
Maman, O., Ahmad, W. A., Perzon, O., Mahlab‐Guri, K., Elbirt, D., & Elinav, H. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09120-7 · Cited by 5
Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors
Pepperrell, T., Venter, F., Moorhouse, M. A., McCann, K., Bosch, B., Tibbatts, M., Woods, J., Sokhela, S. M., Serenata, C. M., & Hill, A. M. (2019) · AIDS · doi:10.1097/qad.0000000000002422 · Cited by 5
Self-citation
The same lesson over and over: drugs alone will not get us to 90--90--90
Cohen, J., Pepperrell, T., & Venter, F. (2020) · AIDS · doi:10.1097/qad.0000000000002494 · Cited by 5
Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
Pohlman, F. W., McGee, K. S., & McKellar, M. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab403 · Cited by 5
Alterações no índice de massa corporal: Coorte em indivíduos em uso de dolutegravir
de Souza, C. R., Ceccato, M. D. G. B., dos Santos, S. F., Mol, M. P. G., & Silveira, M. R. (2021) · Research Society and Development · doi:10.33448/rsd-v10i16.23189 · Cited by 5
Cardiovascular Diseases and Exposure to Integrase Inhibitors: Causal Interpretation of Treatment Effect in Observational Studies
Costagliola, D. G. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad285 · Cited by 5
The Impact of Regular Screening and Lifestyle Modification on Cardiovascular Disease Risk Factors in South African Women Living With HIV
Hanley, S., Moodley, D., Naidoo, M., & Brummel, S. S. (2024) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003387 · Cited by 4
Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-naïve people with human immunodeficiency virus who start DTG/ABC/3TC compared to BIC/FTC/TAF at 48-week follow-up
Cano-Díaz, A. L., González, S. T., Velázquez, G. E. S., Marín, J. A. M., Martínez, J. E. G., & Mauss, S. (2024) · International Journal of STD & AIDS · doi:10.1177/09564624241287886 · Cited by 4
Preswitch Regimens Associated With Weight Gain Among Persons With HIV who Switch to Integrase Inhibitor–Containing Regimens
Cutshaw, M. K., Harding, M., Davenport, C. A., & Okeke, N. L. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae752 · Cited by 4
Comparison of central obesity prevalence among adults living with and without HIV in Botswana: a cross-sectional study
Moshomo, T., Mawi, M., Williams, C. G., Molebatsi, K., Masupe, T., Manyake, K., Lockman, S., Molefe‐Baikai, O. J., Leero, A., Jarvis, J. N., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-096170 · Cited by 4
Epidemiology of Antiretroviral Therapy Related Adverse Drug Reactions and its Predictors Among Patients with Human Immunodeficiency Virus/AIDS in Ethiopia: A Systematic Review and Meta-analysis
Zewdu, W. S., Dagnew, S. B., Zeleke, M. M., Ferede, Y. A., Kassie, A. B., Moges, T. A., & Alemu, M. A. (2025) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/23259582251358929 · Cited by 4
Clinical impact and cost-effectiveness of the WHO-recommended advanced HIV disease package of care
Hyle, E. P., Maphosa, T., Rangaraj, A., Feser, M. K., Singini, G. C., Shrestha, P., Shroufi, A., Reddy, K. P., Matiya, E., Dambe, R., et al. (2025) · The Lancet Global Health · doi:10.1016/s2214-109x(25)00190-1 · Cited by 4
HIV Drug Resistance to Dolutegravir Among Adults Investigated for Antiretroviral Treatment Failure in Malawi: A 2023 National Cross-Sectional Survey
Kalata, N. L., Bello, G., Pals, S. L., Kabaghe, A. N., Mkungudza, J., Bighignoli, B., Panja, L., Bilaal, W., Kusakale, G., Chitenje, M., et al. (2025) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003744 · Cited by 4
Untargeted Metabolite Profile Associations With Body Mass Index, Waist–Hip Ratio, and Antiretroviral Therapy in >1300 People With HIV: The Swiss HIV Cohort Study
Labarile, M., Schoepf, I. C., Pasin, C., Oumelloul, M. A., Thorball, C. W., Riebensahm, C., Surial, B., Wandeler, G., Braun, D. L., Marzolini, C., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf438 · Cited by 4
Type 2 diabetes in people living with HIV: epidemiology, mechanisms, sex differences and early-life determinants
Moreno-López, R., Lazaro-Martin, B., Díez, C., Navarro‐Gómez, M. L., & Tarancón‐Díez, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1734023 · Cited by 4
The pharmacological management of cardiovascular disease in people living with HIV (PLWH)
Corbacho, N., Mur, I., Molas, M. E., Vidal, F., & Domingo, P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1856075 · Cited by 4
The influence of HIV infection and antiretroviral treatment on pulmonary function in individuals in an urban setting in sub-Saharan Africa
van den Berg, O. E., Shaddock, E. J., Stacey, S. L., Feldman, C. H., Barth, R. E., Grobbee, D. E., Venter, F., Klipstein‐Grobusch, K., & Vos, A. G. (2021) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v22i1.1312 · Cited by 4
Self-citation
Prevalence of selected cardiometabolic risk factors in the global ART-naïve HIV infected population: A protocol for a systematic review and meta-analysis
Ebasone, P. V., Peer, N., Dzudié, A., & Kengne, A. P. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286789 · Cited by 4
Inflammatory properties of tenofovir in human liver cells
Vazi, S., van Zyl, S., Wet, R. V. D., & Tiloke, C. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100114 · Cited by 4
Effect of tenofovir alafenamide in combination with and without integrase inhibitors on weight gain, diabetes, and hypertensive disorders of pregnancy
Nissim, O., Haney, A., & Lazenby, G. B. (2023) · Pregnancy Hypertension · doi:10.1016/j.preghy.2023.09.008 · Cited by 4
Pharmacokinetic and toxicological considerations affecting antiretroviral drug dosing in pregnant women
Todorović, Z., Dragović, G., & Lukić, R. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2353762 · Cited by 4
Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy
Eke, A. C., Brummel, S. S., Aliyu, M. H., Stranix‐Chibanda, L., Eleje, G. U., Ezebialu, I. U., Korutaro, V., Wabwire, D., Matubu, A., Mbengeranwa, T. G., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae441 · Cited by 4
Weight and Lipid Levels in People Living With HIV and Initiating a Dolutegravir‐Based Regimen in a Resource Limited Setting
Chakanetsa, R., Chikwati, R. P., Chitungo, I. J. B., Musarurwa, C., Tanyanyiwa, D. M., Manasa, J., & Kouamou, V. (2024) · AIDS Research and Treatment · doi:10.1155/2024/4620951 · Cited by 4
More evidence for dolutegravir as first-line ART for all
Estill, J. A. M., & Bertisch, B. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(19)30414-x · Cited by 4
Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir/lamivudine/dolutegravir
Hamzah, L., & Post, F. A. (2020) · AIDS · doi:10.1097/qad.0000000000002742 · Cited by 4
Enabling timely HIV postexposure prophylaxis access in sub-Saharan Africa
Phillips, A. N., Sibanda, E. L., Sikwese, K., Bansi‐Matharu, L., Cambiano, V., Rodger, A. J., Lundgren, J. D., Shahmanesh, M., Gilks, C. F., Godfrey, C. C., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003258 · Cited by 4
Insulin Resistance is Associated with Higher Plasma Viral Load Among HIV-Positive Adults Receiving Longer-Term (1 Year) Combination Antiretroviral Therapy (ART).
Mulenga, L., Musonda, P., Chirwa, L., Siwingwa, M., Mweemba, A., Suwilanji, S., Fwoloshi, S., Phiri, H., Phiri, D. C., Mulenga, P., et al. (2019) · PubMed · Cited by 4
Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV
Hsu, R. K., Brunet, L., Fusco, J. S., Mounzer, K., LaMori, J. C., & Fusco, G. (2022) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0188 · Cited by 4
Changes in Leptin to Adiponectin Ratio After Antiretroviral Therapy: A Pilot Observational Study
Hikasa, S., Shimabukuro, S., Hideta, K., Higasa, S., Sawada, A., Tokugawa, T., Tanaka, K., Yanai, M., & Kimura, T. (2023) · Current HIV Research · doi:10.2174/1570162x21666230327165902 · Cited by 4
Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV
Erlandson, K. M., Mohaweche, R., Morrow, M., MaWhinney, S., Khuu, V., Boyd, M., Balasubramanyam, A., Melanson, E. L., & Lake, J. E. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad363 · Cited by 4
From Evidence to Effectiveness: Implications of the Randomized Trial to Prevent Vascular Events in HIV Study for People With HIV in Low- and Middle-Income Settings
Manne‐Goehler, J., Ali, M. K., Flood, D., Marconi, V. C., Venter, F., & Siedner, M. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad702 · Cited by 4
Fixed-dose antiretroviral combinations in children living with human immunodeficiency virus type 1 (HIV-1): a systematic review
Attaianese, F., Dalpiaz, I., Failla, M., Pasquali, E., Galli, L., & Chiappini, E. (2023) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2297095 · Cited by 4
Clinical Trials That Have Changed Clinical Practice and Care of Pregnant People With HIV
Fisher, S. A., Madden, N., Espinal, M., Garcia, P. M., Jao, J. K., & Yee, L. M. (2024) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000860 · Cited by 4
High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda
Segujja, F., Omooja, J., Lunkuse, S., Nanyonjo, M., Nabirye, S. E., Nassolo, F., Bugembe, D. L., Bbosa, N., Kateete, D. P., Ssenyonga, W., et al. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2019.0279 · Cited by 4
Evaluation of the impact of delayed centrifugation on the diagnostic performance of serum creatinine as a baseline measure of renal function before antiretroviral treatment
Chikomba, C. E., Padoa, C. J., & Tanyanyiwa, D. M. (2020) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v21i1.1056 · Cited by 4
Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV
Han, W. M., Kerr, S. J., Avihingsanon, A., & Boettiger, D. C. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac306 · Cited by 4
Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV
Sribenjalux, W., Nuntawit, T., Meesing, A., & Chetchotisakd, P. (2022) · International Journal of STD & AIDS · doi:10.1177/09564624221137972 · Cited by 4
Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis
Selvaraj, S. V., Bares, S. H., & Havens, J. P. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa454 · Cited by 4
Dolutegravir Reported Adverse Drug Reactions: A Systematic Review ProtocolPreprint
Wadesango, L., Wiafe, E., Padayachee, N., Mensah, K. B., & Bangalee, V. (2021) · Research Square · doi:10.21203/rs.3.rs-882616/v1 · Cited by 4
Cabotegravir – global access to long-acting pre-exposure prophylaxis for HIVPreprint
Pepperrell, T., Cross, S., & Hill, A. (2022) · Research Square · doi:10.21203/rs.3.rs-2198548/v2 · Cited by 4
Self-citation
HIV-1 latency: From acquaintance to confidant
Yang, C., Tong, L., & Xue, J. (2025) · Journal of Virus Eradication · doi:10.1016/j.jve.2025.100597 · Cited by 3
Virological treatment failure and associated factors among adults on first-line antiretroviral therapy in West Hararghe, Ethiopia
Zerihun, E., Tesema, K., & Abera, F. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1440504 · Cited by 3
Dyslipidemia and Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy in Central Uganda
Timbigamba, F., Bagenda, C. N., Sembogga, H., Wasswa, T., Bazibu, F., Ssali, J., Ssemwanga, E., Mugisa, M. J., Nuwagaba, E., Ojuko, S., et al. (2025) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/23259582251395549 · Cited by 3
Virological failure in a pediatric cohort on a dolutegravir based regimen: a retrospective study in northwest Ethiopia, 2017–2023
Zewdu, W. S., Zeleke, M. M., Ferede, Y. A., Kassie, A. B., Alemu, M. A., & Moges, T. A. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1442215 · Cited by 3
Enhanced immune recovery with B/F/TAF compared with DTG/3TC in HIV patients: A prospective observational study
Fan, R., Zhao, Y. H., Li, C.-Y., Cao, W.-J., Wang, J., Zhu, X.-H., Zhou, X., Zou, M., & Qin, G. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.103055 · Cited by 3
Association between transitioning to a dolutegravir-based regimen and risk of incident hypertension in adults with HIV in West Africa: a multicentre target trial emulation study
Millot, R., Tiendrebeogo, T., Ezechi, O., Poda, A., Minga, A. K., Malateste, K., Ofotokun, I., Ekouévi, D. K., & Jaquet, A. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103584 · Cited by 3
Evaluation of tenofovir alafenamide– versus tenofovir disoproxil fumarate–containing regimens on renal outcomes: systematic literature review and meta-analysis
Liang, X., Park, K. Y., Lee, H., Liu, H., Willis, C., Dhippayom, T., Rogers, R., Weinberg, A. R., Green, J., Chi, A., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04628-9 · Cited by 3
Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-world, Prospective, Observational Cohort Study
Li, A., Li, Z., Li, J., Gao, Y., Dai, L., Liu, A., Zhang, H., Wang, X., Wu, L. S., Yao, Y., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf808 · Cited by 3
HIV Genetic Diversity, Virological Failure, and Drug Resistance in Libreville, Capital of Gabon, before a Total Dolutegravir-Based Regimen Transition
Bivigou‐Mboumba, B., Iroungou, B. A., Moussavou-Boundzanga, P., Mangouka, L. G., Akombi, F. L., Bouassa-Bouassa, A., François-Souquière, S., & Nzenze, J. R. (2022) · World Journal of AIDS · doi:10.4236/wja.2022.123012 · Cited by 3
Longitudinal trajectories of weight changes among people living with HIV on antiretroviral therapy: A group-based study
Wu, X., Zhang, L., Lu, Z., Li, Y., He, Y., Zhao, F., Peng, Q., Zhou, X., Wang, H., & Zou, H. (2023) · iScience · doi:10.1016/j.isci.2023.108259 · Cited by 3
A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV
Ashta, K. K., Arora, S., Khanna, R., Raman, N., Anilkumar, A., & Mohan, C. (2024) · Current HIV Research · doi:10.2174/011570162x264021231108010324 · Cited by 3
Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study
Abe, K., Imamura, J., Sasaki, A., Suzuki, T., Kamio, S., Obara, T., & Ito, T. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00336-y · Cited by 3
Morbidity and Mortality Risk Among People With HIV and Central or Visceral Adiposity: A Targeted Literature Review
Bjornson, A. M., Bedimo, R., Szabo, S. M., Rochon, H., & Lee, D. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae543 · Cited by 3
Steatotic liver disease in people with HIV at Tshepong Hospital: A post-mortem analysis
Moosa, A., Variava, E., Calver, A. D., Chita, G., Sabet, N., Ngwenya, S., Papathanasopoulos, M. A., & Omar, T. (2024) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v25i1.1638 · Cited by 3
Is CD4 + T‐cell recovery ‐ Associated with hypertension during initial antiretroviral therapy in human immunodeficiency virus patients?
Bursztyn, M., & Israel, S. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13976 · Cited by 3
Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1
Donga, P. Z., Émond, B., Rossi, C., Bookhart, B., Lee, J., Caron‐Lapointe, G., Wei, F., & Lafeuille, M. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s413800 · Cited by 3
Glycemic Control in Patients Living With HIV Initiated on Integrase Inhibitor–Based Three-Drug Antiretroviral Therapy
Gerber, A., Fischetti, B., Popova, O., & Longo, M. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225231221059 · Cited by 3
Beyond the Numbers: Weight Gain Risk Factors, Implications, and Interventions among Individuals with HIV
Patel, Y. S., & Malvestutto, C. (2024) · Journal of AIDS and HIV Treatment · doi:10.33696/aids.6.047 · Cited by 3
Studying the Changes in Physical Functioning and Oxidative Stress-Related Molecules in People Living with HIV after Switching from Triple to Dual Therapy
Cusato, J., Mulasso, A., Ferrara, S. M., Manca, A., Antonucci, M., Accardo, G., Palermiti, A., Bianco, G., Chiara, F., Mula, J., et al. (2024) · Antioxidants · doi:10.3390/antiox13050518 · Cited by 3
Challenges for Novel Antiretroviral Development in an Era of Widespread tenofovir-disoproxil/lamivudine (or emtricitabine)/dolutegravir availability (TLD) Availability
Fairhead, C., Levi, J., & Hill, A. M. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae361 · Cited by 3
Self-citation
The effect of dolutegravir on obstetrical outcomes among women living with HIV : A retrospective cohort study
Naimi, A. A., Chang, C. A., Rawizza, H. E., Olaifa, O., Ogunsola, O. O., Okonkwo, P., & Kanki, P. J. (2025) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.16349 · Cited by 3
Pharmacokinetics of HIV therapies in pregnant patients: an update
Neary, M., Owen, A., & Olagunju, A. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1754792 · Cited by 3
High individual pain variability in people living with HIV: A graphical analysis
Wadley, A. L., Venter, F., Moorhouse, M. A., Akpomiemie, G., Serenata, C. M., Hill, A., Sokhela, S. M., Mqamelo, N., & Kamerman, P. R. (2020) · European Journal of Pain · doi:10.1002/ejp.1658 · Cited by 3
Self-citation
What's new in bone disease and fractures in HIV?
Álvarez-Barco, E., & Mallon, P. W. G. (2021) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000682 · Cited by 3
Highlights of the 10th International AIDS Society (IAS) Conference on HIV Science, 21–25 July 2019, Mexico City, Mexico
Psomas, C. K., Waters, L. J., Barber, T., Fidler, S. J., Macartney, M. J., Alagaratnam, J., Perera, B., & Loes, S. K. (2019) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30035-2 · Cited by 3
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
Titanji, B. K., Hernández-Romieu, A. C., & Adelman, M. W. (2021) · Annals of Internal Medicine · doi:10.7326/l20-1398 · Cited by 3
Impact of transition to Dolutegravir-based antiretroviral therapy on virological suppression among children living with HIV in Southern Nigeria: A before and after analysis of program dataPreprint
Ani, I., Iyamu, I. O., Akpan, U., Nwanja, E., Onwah, O., Toyo, O., Gana, B., Joseph, U. C. A., Okolo, C., Usang, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5434482/v1 · Cited by 3
Protocol for the LIFEH project: a prospective observational study to explore lifestyle among people living with HIV experiencing weight gain, looking beyond antiretroviral therapy
Zanini, B., Salvi, M., Marconi, S., Tiecco, G., Gilberti, G., Castellano, M., & Quirós-Roldán, E. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086866 · Cited by 2
A combined prospective and retrospective comparative study evaluating renal outcomes after switching from TDF + FTC + EFV to TDF/3TC/DTG (TLD) vs. DTG + 3TC in virologically suppressed Thai people with HIV
Patamatamkul, S., Burimat, P., Kanogtorn, S., & Putcharoen, O. (2025) · HIV Research & Clinical Practice · doi:10.1080/25787489.2025.2509379 · Cited by 2
Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France
Sagaon‐Teyssier, L., Eremin, A., Valantin, M., Fauchois, A., Tubiana, R., Seang, S., Schneider, L., Fayçal, A., Saliba, S., Wirden, M., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf307 · Cited by 2
Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen
Orkin, C. M., Koethe, J. R., Kumar, P. N., Sklar, P. A., Xu, Z. J., Plank, R. M., Greaves, W. L., & Lahoulou, R. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf639 · Cited by 2
Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy
Hulgan, T., Erlandson, K. M., Bradford, Y., Tassiopoulos, K., Wu, K., Bares, S. H., Brown, T. T., Lake, J. E., Leonard, M. A., McComsey, G. A., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf696 · Cited by 2
Risk factors of metabolic dysfunction-associated fatty liver disease in people with HIV receiving antiretroviral therapy
Yuan, R., Yan, Y., Deng, L., Li, F. R., Chen, Q., Gui, X., Xiong, Y., & Yang, R. (2025) · AIDS · doi:10.1097/qad.0000000000004419 · Cited by 2
Longitudinal analysis of metabolic changes in people with HIV on integrase inhibitor-based versus efavirenz-based therapy: a prospective real-world cohort study in China
Tao, M., Xia, M., Yu, T., Li, B., Peng, J., Sh, C., & Xu, X. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12553-x · Cited by 2
Metabolic dysfunction-associated steatotic liver disease linked to antiretroviral exposure in cohort of people with HIV
Lindhardt, M. S., Jensen, L. R., Meddis, A., Gluud, L. L., & Benfield, T. (2026) · AIDS · doi:10.1097/qad.0000000000004462 · Cited by 2
Efficacy of dolutegravir-based therapy in achieving virological suppression in PLHIV in low- and middle-income countries: real-world evidence from a large clinical cohort in Cameroon
Tadenfok, C. N., Fokam, J., Semengue, E. N. J., Mossiang, L., Oyie, S., Noumo, P., Ngia, J., Beloumou, G. A., Djupsa, S. C. N., Nka, A. D., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13013-2 · Cited by 2
Virological outcomes of dolutegravir-based versus other antiretroviral regimens in people living with HIV: A systematic review and meta-analysis
Weldemhret, L., Dejene, T. A., Gebrehiwot, G. T., Legese, H., Wasihun, A. G., & Weldemariam, A. G. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13098-9 · Cited by 2
Latent HIV Reservoirs in the Central Nervous System: Mechanisms, Barriers, and Therapeutic Approaches
Matthew, Y., Foley, N., Claiborne, D. T., Klase, Z. A., & Dick, A. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c01103 · Cited by 2
Comparing implications of cardiovascular risk of abacavir and integrase inhibitors: why scientific community is confused and timid?
Guaraldi, G., & Milić, J. (2023) · AIDS · doi:10.1097/qad.0000000000003518 · Cited by 2

Authors: Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., Norris, S., Chersich, M., Clayden, P., Abrams, E., Arulappan, N., Vos, A., McCann, K., Simmons, B., & Hill, A.
Affiliations: From Ezintsha (W.D.F.V., M. Moorhouse, S.S., N.M., C.S., G.A., N.C., N.A., A.V.), Wits Reproductive Health and HIV Institute, Faculty of Health Sciences (W.D.F.V., M. Moorhouse, S.S., L.F., N.M., M. Masenya, C.S., G.A., N.C., M.C., N.A., A.V.), and the South African Medical Research Council Developmental Pathways for Health Research Unit, Department of Pediatrics, School of Clinical Medicine, Faculty of Health Sciences (S.N.), University of the Witwatersrand, Johannesburg; the Faculty of Medicine,...
South African Medical Research Council (ZA)
ORCID: Venter, Willem D.F.
Moorhouse, Michelle
Sokhela, Simiso
Fairlie, Lee
Mashabane, Nkuli
Masenya, Masebole
Serenata, Celicia
Akpomiemie, Godspower
Qavi, Ambar
Chandiwana, Nomathemba
Norris, Shane
Chersich, Matthew
Clayden, Polly
Abrams, Elaine
Arulappan, Natasha
Vos, Alinda
McCann, Kaitlyn
Simmons, Bryony
Hill, Andrew
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-08-29
Volume: 381
Issue: 9
Pages: 803-815
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1902824
OpenAlex: W2962964639
Cited by: 723
References: 31
Citations by year: 2026: 65 · 2025: 84 · 2024: 117 · 2023: 110 · 2022: 90 · 2021: 112 · 2020: 120 · 2019: 25
FWCI: 66.47
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
ePrints Soton (University of Southampton) (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion)
Funders: UNITAID (2016-07-Wits RHI)
U.S. Agency for International Development (AID-OAA-A-15-00069)
South African Medical Research Council
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: dolutegravir, tenofovir alafenamide, tenofovir disoproxil fumarate, HIV-1 infection, antiretroviral therapy, triple therapy, emtricitabine, efavirenz, non-inferiority, viral suppression, treatment discontinuation, low- and middle-income countries, South Africa
MeSH terms: Dolutegravir, Adenine, Adolescent, Adult, Drug Therapy, Combination, Female, Heterocyclic Compounds, 3-Ring, Humans, Male, Middle Aged, Oxazines, Phosphorous Acids, Piperazines, Pregnancy, Pregnancy Complications, Infectious, Prodrugs, Pyridones, RNA, Viral, Uracil, HIV-1, Bone Density, HIV Infections, CD4 Lymphocyte Count, HIV Integrase Inhibitors, Viral Load, Anti-Retroviral Agents, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks